Prof John G Gribben

Professor and Consultant Haematologist
John G Gribben

Professor Gribben specialises in haematological cancers including lymphomas, leukaemias and bone marrow transplantation.

Haematology, Oncology
In-person, Video call


Professor John Gribben graduated from the University of Glasgow in 1980. He subsequently trained in Haematology at University College London and in Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School, where he remained on the faculty for 17 years before returning to the UK.

He specialises in haematological cancers including lymphomas, leukaemias and bone marrow transplantation.

His NHS post is as Consultant Haematologist and Medical Oncologist Barts and The London NHS Trust.

He is the author of more than 300 articles and chapters in peer-reviewed publications and has a global reputation for his work in researching new drugs and forms of cancer treatment. He has grant funding from The National Cancer Institute and Cancer Research UK for pioneering studies in leukaemia and lymphoma.

He has sat on and chaired numerous international executive committees dedicated to investigating new approaches to cancer care, and several of the editorial boards for professional publications which are focused on cancer. He has lectured across the world on new therapies for cancer treatment.

More information

Professor John G Gribben is available through The London Clinic's Connect service for video consultations.

Book a video call now

Call or email the consultant's secretary Kim Bergmann.

Send an email


  • Professor and Consultant Medical Oncologist
    Barts and The London NHS Trust
  • Professor of Experimental Cancer Medicine
    Barts and The London School of Medicine, Queen Mary University of London
  • University of Glasgow
  • University College London
  • Harvard Medical School

CART-cell therapy

Middle East Medical Portal


Professor John G Gribben explains why CART-cell therapy has the potential to revolutionise cancer treatment.

Q&A: Professor John Gribben

Marylebone Journal


Consultant haematologist at The London Clinic on CAR T cell therapy, which has the potential to revolutionise cancer treatment.

How 53-year-old retail worker became one of the first NHS patients to be saved by ‘miracle’ cancer treatment

Professor Gribben is quoted in this Daily Mail news report on a pioneering immunotherapy treatment.

Q&A: Prof John Gribben

Marylebone Journal

Professor Gribben's interview with the Marylebone Journal sees him talk stem cells, research and the immune system.


Contact us

Request an appointment with our world-leading consultants today, or speak to our helpful advisors for tailored advice.